Journal
CELL REPORTS
Volume 15, Issue 2, Pages 274-287Publisher
CELL PRESS
DOI: 10.1016/j.celrep.2016.03.037
Keywords
-
Categories
Funding
- Belgian grants (Interuniversity Attraction Poles) [IAP 7/32]
- Flemish grants (Research Foundation Flanders) [FWO G.0875.11, FWO G.0973.11, FWO G.0A45.12N, FWO G.0787.13N, FWO G.0A54.13N, FWO G.0607.13N, FWO G0E04.16N]
- Methusalem grant [BOF09/01M00709, BOF16/MET_V/007]
- Ghent University grants (MRP, GROUP-ID consortium)
- Foundation against Cancer [F2012-188]
- VIB
- FWO postdoctoral grant
- FWO (Research Foundation Flanders)
- Methusalem grant
- FWO postdoctoral grants
Ask authors/readers for more resources
Successful immunogenic apoptosis in experimental cancer therapy depends on the induction of strong host anti-tumor responses. Given that tumors are often resistant to apoptosis, it is important to identify alternative molecular mechanisms that elicit immunogenic cell death. We have developed a genetic model in which direct dimerization of FADD combined with inducible expression of RIPK3 promotes necroptosis. We report that necroptotic cancer cells release damage-associated molecular patterns and promote maturation of dendritic cells, the cross-priming of cytotoxic T cells, and the production of IFN-gamma in response to tumor antigen stimulation. Using both FADD-dependent and FADD-independent RIPK3 induction systems, we demonstrate the efficient vaccination potential of immunogenic necroptotic cells. Our study broadens the current concept of immunogenic cell death and opens doors for the development of new strategies in cancer therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available